Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application.
about
B-Raf and the inhibitors: from bench to bedsidePotential Role of JAK-STAT Signaling Pathway in the Neurogenic-to-Gliogenic Shift in Down Syndrome BrainBlinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemiaNovel agents and biomarkers for acute lymphoid leukemiaSignal transduction inhibitors in treatment of myelodysplastic syndromesBCR-ABL affects STAT5A and STAT5B differentiallyA novel one-class SVM based negative data sampling method for reconstructing proteome-wide HTLV-human protein interaction networks.STAT inhibitors for cancer therapy.MEK and the inhibitors: from bench to bedside.A case of pediatric B-Lymphoblastic leukemia presenting with a t(9;12)(p24;q11.2) involving JAK2 and concomitant MLL rearrangement with apparent insertion at 6q27AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells.Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivoAutomation of a phospho-STAT5 staining procedure for flow cytometry for application in drug discovery.Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTPε and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma.Identification of a natural product-like STAT3 dimerization inhibitor by structure-based virtual screening.Anti-inflammatory effects of dabrafenib in vitro and in vivo.Different mutations of the human c-mpl gene indicate distinct haematopoietic diseasesActivating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma.JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasmsPhosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.Identification of myeloproliferative neoplasm drug agents via predictive simulation modeling: assessing responsiveness with micro-environment derived cytokines.Ibrutinib for B cell malignancies.Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemiaIbrutinib and novel BTK inhibitors in clinical development.Role of IL-9 and STATs in hematological malignancies (Review).The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer.Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives.Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.Novel ALK inhibitors in clinical use and development.AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.A comprehensive review of pacritinib in myelofibrosis.Proteomic Approaches for Biomarker Panels in Cancer.A rare case of primary cutaneous follicle centre lymphoma presenting as a giant tumour of the scalp and combined with JAK2V617F positive essential thrombocythaemia.ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.Incidence of hematologic malignancy and cause-specific mortality in the Women's Health Initiative randomized controlled trial of calcium and vitamin D supplementation.Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cellsSteroid Hormone Receptor Coregulators in Endocrine Cancers.Knock-down of BCL6 / STAT6 sensitizes primary B cell lymphoma cells for treatment with current therapeutic agents.Vanadium pentoxide prevents NK-92MI cell proliferation and IFNγ secretion through sustained JAK3 phosphorylation.Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.
P2860
Q21198860-37F9B4C4-50EE-4E78-9460-7827B5F58878Q26765647-BE61EC59-784F-40DD-B2B7-07E531455E7BQ26785828-C81041BF-41FA-4A20-BDFD-8865E9DC78E3Q26829775-37C40C96-03E2-42D8-ADD8-52BC2C1A6518Q26829903-7998D022-1774-491E-B9DE-0FDDEE20A3E6Q28538914-B03A85A9-F198-4AED-9EF3-310A09E452B2Q30843915-932170A8-AC6E-45F8-A279-C2D42BB8CB47Q33644206-7C3F0C59-06B1-4ADA-A6F7-313C2807B905Q34036341-368244B7-9604-4CC5-94B2-F067561DEFEBQ34256192-B330199E-F974-4A4F-8D02-F69B316EA7C9Q34334399-7D66000E-D6C0-4AEE-936D-BDD30064414EQ34634316-34FC9C27-6C5B-425A-9093-96039DE9F468Q35343741-71E0813A-3259-4122-9B72-C47A5D350FA5Q35934532-B92D2808-4BCF-4121-8C1D-1A9BD072A173Q36179596-457862D7-EDE6-4FBC-B0EA-EB5EE5E143ADQ36273868-5BF86D88-FE95-4474-A829-82E15C685D90Q36585086-31C91219-F082-4815-8497-D5759F0C137FQ36905691-C1B3114F-190B-4AED-BEF5-587B43AD0512Q37168138-46B59867-949E-451C-9F11-AB322D423A8AQ37350230-DB721EE5-A9A0-4630-8728-DAD982F8835EQ37392623-7114A458-4416-4E92-8A2B-5BEE7052F8A1Q37555418-6382AE14-376A-46FF-8496-648449C3DA54Q37702629-2C5E8C73-2BB3-41E2-9702-2BB97EC9CF66Q38130010-4D3096BB-D445-4F76-9AA8-A6C164D8AA2BQ38187410-3952081E-717C-4BB0-A42C-8983BEECD0BAQ38203779-8359EFB5-2B16-40C7-B15D-4F03B34620EDQ38251801-E2D3F1B2-742B-4ED4-9C4B-69AB43C9F877Q38260357-BFAB1E6E-7E0A-45C6-8084-6D12240BA5EBQ38427240-9398D631-CC48-42A1-82F6-287E8B70EE5DQ38558611-2D29A03E-D4F9-43CA-AB0F-EDC837FA831EQ38586421-69174C49-7984-4306-B97B-0E5801DBD4EEQ38632577-CF8C3909-76A2-4FAB-9BE5-57A44211DC31Q38637619-F09657B4-F620-44AE-B16D-D39076AB6A54Q38640917-8A8D0BE9-00E6-4959-BC25-37F678143012Q38707181-5B2AD91C-6555-426F-9875-EFB8397FE259Q38741546-CEBBFD05-F6B8-48F6-8018-597084F74753Q38848340-410400FD-507B-4BEC-8FBE-E42748DD0D73Q38919386-6B59DA3E-E18F-4109-A008-30C133B60386Q38922507-DA80F924-CFA5-42F6-9D74-9342A3B8D2D6Q38962315-20882D20-E94A-4E1A-BB08-943F942374A9
P2860
Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Dysregulation of JAK-STAT path ...... tors for clinical application.
@en
type
label
Dysregulation of JAK-STAT path ...... tors for clinical application.
@en
prefLabel
Dysregulation of JAK-STAT path ...... tors for clinical application.
@en
P2093
P2860
P356
P1433
P1476
Dysregulation of JAK-STAT path ...... tors for clinical application.
@en
P2093
Delong Liu
Muhammad Furqan
Nikhil Mukhi
P2860
P2888
P356
10.1186/2050-7771-1-5
P577
2013-01-16T00:00:00Z
P5875
P6179
1036430934